Equity Overview
Price & Market Data
Price: $2.43
Daily Change: $0.00 / 0.00%
Daily Range: $2.12 - $2.68
Market Cap: $280,157,216
Daily Volume: 2,557,710
Performance Metrics
1 Week: -4.71%
1 Month: -21.86%
3 Months: -38.94%
6 Months: -37.05%
1 Year: 212.2%
YTD: -38.94%
Company Details
Employees: 32
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.